Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Net Interest Income

Last Annual Value

16.52M

3-Year CAGR

275%

5-Year CAGR

%

10-Year CAGR

%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Net Interest Income

TRML · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
16.52M
71.3%N/AN/A 
9.30M
-16.8%203.7%N/A
16.12M
50.1%176.4%N/A
16.01M
10.2%273.6%N/A
0.00
N/AN/AN/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
-652.00K
N/AN/AN/A
27.04M
-4.5%100.7%N/A
-11.05M
N/AN/AN/A
14.59M
4.2%143.6%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98